GeparPiPPa / GBG105GeparPiPPa / GBG105Recruiting

Effect of the PIK3 inhibitor inavolisib, added to anti-hormone therapy and HER2 inhibitors, on the treatment of HER2- and hormone receptor-positive breast cancer when breast cancer cells have a PIK3CA mutation

Gender
Women
Age
18 years and older
Trial type
Interventional
Line of therapy
First line
Phase
Phase II

What is this trial about?

In breast cancer, a specific change in the tumor cells (known as the ) may be present, which impairs the response to a standard first phase of therapy (neoadjuvant). Therefore, researchers are investigating whether a new drug that targets PIK3CA () could offer a way to improve the response to neoadjuvant anti-hormone therapy. The goal of the GeparPiPPA study is to evaluate the efficacy and safety of inavolisib in combination with an established treatment regimen consisting of anti-hormone therapy and blockade. Adult women and men with early-stage breast cancer are eligible to participate. The breast cancer must be -positive and HER2-positive and must have a PIK3CA mutation.

Detailed description

Breast cancer (mammary carcinoma) is a malignant disease of the breast gland tissue characterized by the uncontrolled proliferation of breast gland cells. Treatment of the disease depends on numerous factors, such as the patient’s overall health, the stage of the disease, the presence of detectable hormone receptors on the surface of the cancer cells (-positive, progesterone receptor-positive), and the increased expression of the HER2 receptor on the cells (HER2-positive). If hormone receptors are present on the surface of the cancer cells, the tumor responds to the hormones estrogen and/or by growing. In these cases, anti-hormone therapy may be administered. HER2 expression is another common characteristic of breast cancer cells; when present in higher amounts, it also promotes cell growth. In many treatment strategies, it serves as a targeted point of attack for inhibiting tumor growth. In this study, dual inhibition is achieved using a fixed-dose combination of two drugs that target the HER2 receptor ( and ).

In up to 30% of patients with breast cancer, the cancer cells carry a PIK3CA mutation. A major problem here is that standard chemotherapy and anti-hormone therapy are less effective in these cases. The study drug, inavolisib, is a so-called that specifically blocks the activated by the . This is intended to restore the effectiveness of the other therapies.

The goal of the GeparPiPPA study is to investigate whether adding Inavolisib to standard anti-hormone therapy and HER2 blockade can lead to a better response to treatment. This is a Phase 2 study in which patients are randomly assigned to two groups: one group receives inavolisib daily in addition to their , while the other does not. All participants are aware of their assignment (open-label). Standard therapy consists of HER2 inhibitors and anti-hormone therapy. Patients receive a fixed combination of pertuzumab and trastuzumab (PH-FDC SC) as a HER2 inhibitor, administered via injection every three weeks. For antihormonal therapy, either or an plus a analog is used, depending on the treating physician’s choice.

Treatment lasts 18 weeks, followed by surgery or a . Three weeks after the end of treatment, the rate of patients who are completely disease-free (= complete ) is assessed using a tissue sample or as part of the standard breast surgery. Eligible participants include women and men aged 18 and older with untreated early-stage HER2-positive, hormone receptor-positive breast cancer. The disease must also have a PIK3CA mutation, and the tumor must be at least 1 cm in size.

Facts

  1. What disease: -positive, -positive breast cancer with a
  2. Cancer characteristics: Untreated, tumor size ≥ 1 cm, early stage
  3. What the study investigates: with or without combination therapy involving HER2 blockade ( + ) and anti-hormonal therapy ( or an ± a analog)
  4. Study objective: To evaluate the effect of inavolisib on the pathological complete response (pCR) rate in breast cancer
  5. Study duration: 18 weeks of treatment plus after surgery/ (3 weeks later)
  6. Study characteristics: Two , open-label (unblinded), (random), Phase 2 study

Trial sites

47 trial sites in Germany are listed. Find a site near you.

  • Haematologie-Onkologie im Zentrum MVZ GmbH

    Halderstrasse 29, 86150 Augsburg

    Recruiting
  • DBZ Onkologie GmbH

    Hoenower Strasse 31-33, 12623 Berlin

    Recruiting
  • Helios Klinikum Berlin-Buch GmbH

    Schwanebecker Chaussee 50, 13125 Berlin

    Status unknown
  • Klinik für Gynäkologie und Geburtshilfe, Brustzentrum/Studiensekretariat

    Berlin

    Recruiting
  • Praxisklinik Krebsheilkunde Fuer Frauen

    Berlin

    Recruiting
  • Onkologische Schwerpunktpraxis

    Teutoburger Strasse 60, 33604 Bielefeld

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.